Skip to main content
. 2023 May 15;14:1165471. doi: 10.3389/fendo.2023.1165471

Table 2.

Changes in HbA1c at each follow-up.

  CGM non-users CGM users P-value
N HbA1c (%) N HbA1c (%)  
Baseline (mean ± SD) 310 7.5 ± 1.2 155 7.5 ± 1.2  
At 3 months (mean ± SD) 256 7.6 ± 1.2 155 7.2 ± 1.1  
 Changes from baseline to 3 months (mean ± SD) −0.1 ± 1.0 −0.4 ± 0.8 <0.001b
 P-value for the mean difference from baseline to 3 months 0.324a <0.001a  
At 6 months (mean ± SD) 230 7.4 ± 1.2 154 7.1 ± 1.2  
 Changes from baseline to 6 months (mean ± SD) −0.1 ± 1.0 −0.4 ± 1.0 0.003b
 P-value for the mean difference from baseline to 6 months 0.09a <0.001a  
At 9 months (mean ± SD) 210 7.5 ± 1.2 155 7.0 ± 1.1  
 Changes from baseline to 9 months (mean ± SD) −0.2 ± 1.1 −0.5 ± 1.0 0.007b
 P-value for the mean difference from baseline to 9 months 0.019a <0.001a  
At 12 months (mean ± SD) 310 7.5 ± 1.2 155 7.0 ± 1.1  
 Changes from baseline to 12 months (mean ± SD) −0.01 ± 1.0 −0.5 ± 1.0 0.003b
 P-value for the mean difference from baseline to 12 months 0.816a <0.001a  

CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c; SD, standard deviation.

aP-values were derived from a paired t-test.

bP-values were derived from a two-sample t-test.